MorphoSys AG (ETR:MOR) shares hit a new 52-week high during trading on Wednesday . The stock traded as high as €114.70 ($133.37) and last traded at €114.40 ($133.02), with a volume of 86915 shares changing hands. The stock had previously closed at €111.30 ($129.42).
MOR has been the subject of several recent analyst reports. HSBC set a €81.00 ($94.19) price target on shares of MorphoSys and gave the stock a “sell” rating in a report on Friday, August 16th. Royal Bank of Canada set a €130.00 ($151.16) target price on shares of MorphoSys and gave the company a “buy” rating in a research report on Tuesday, November 19th. Independent Research set a €110.00 ($127.91) target price on shares of MorphoSys and gave the stock a “neutral” rating in a research note on Friday, November 1st. JPMorgan Chase & Co. set a €130.00 ($151.16) price target on shares of MorphoSys and gave the stock a “buy” rating in a research report on Monday, November 18th. Finally, Goldman Sachs Group set a €114.00 ($132.56) price target on shares of MorphoSys and gave the stock a “neutral” rating in a research report on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of €119.86 ($139.37).
The company has a debt-to-equity ratio of 9.78, a current ratio of 7.80 and a quick ratio of 7.63. The stock has a market capitalization of $3.62 billion and a price-to-earnings ratio of -37.61. The stock has a 50 day moving average price of €101.84 and a 200-day moving average price of €98.76.
MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.
See Also: Consumer Price Index (CPI)
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.